Overview & Diagnosis

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting 8–13% globally. It is a leading cause of anovulatory infertility and is associated with long-term metabolic risks including type 2 diabetes, cardiovascular disease, and endometrial cancer.

Rotterdam Criteria (2003) — diagnosis requires 2 of 3:

  • Oligo- or anovulation (irregular or absent periods)
  • Clinical or biochemical hyperandrogenism (elevated testosterone, DHEAS, or clinical signs: hirsutism, acne, alopecia)
  • Polycystic ovaries on ultrasound (≥20 follicles per ovary or ovarian volume >10 mL)

PCOS phenotypes vary significantly — some women have all three criteria (classic PCOS), others only two. This heterogeneity partly explains variable research findings and why individualized management is important.

Other conditions to exclude: Thyroid dysfunction, congenital adrenal hyperplasia, hyperprolactinemia, and Cushing syndrome can mimic PCOS and should be ruled out.

Hormonal & Metabolic Mechanisms

  • Hyperandrogenism: Elevated LH:FSH ratio stimulates ovarian theca cells to produce excess androgens (testosterone, androstenedione), disrupting follicular development and causing anovulation
  • Insulin resistance: Present in 50–70% of PCOS patients regardless of BMI; excess insulin stimulates ovarian androgen production, worsening hyperandrogenism in a vicious cycle
  • Adipose tissue: Visceral adiposity worsens insulin resistance and androgen excess; however, PCOS also occurs in lean women (20–30% of cases) — insulin resistance can be present without obesity
  • Chronic low-grade inflammation: PCOS is associated with elevated CRP and inflammatory markers, which further worsen insulin signaling and ovarian function
  • Gut microbiome: Emerging evidence shows altered gut microbiome composition in PCOS, with reduced microbial diversity linked to insulin resistance and androgen levels
  • Long-term metabolic risks: 30–40% lifetime risk of type 2 diabetes; 50% increased cardiovascular disease risk; 3x higher risk of endometrial cancer (due to anovulatory estrogen exposure without progesterone opposition)

Dietary Approaches for PCOS

Diet is a cornerstone of PCOS management, particularly through its effects on insulin resistance and androgen levels:

  • Caloric restriction and weight loss: Even 5–10% weight loss in overweight PCOS women significantly reduces testosterone, LH:FSH ratio, and insulin; improves menstrual regularity and ovulation in 55–100% of cases in trials
  • Low glycemic index (low-GI) diet: Reduces postprandial insulin spikes; multiple trials show improvements in insulin sensitivity, testosterone, and menstrual frequency vs standard diet
  • Low-carbohydrate diet: Produces greater insulin and androgen reduction than calorie-matched low-fat diet in PCOS; 2005 trial showed 36% reduction in fasting insulin with low-carb vs 3% with low-fat
  • Mediterranean diet: Anti-inflammatory; reduces insulin resistance; evidence for PCOS-specific benefit is emerging; high palatability and sustainability
  • Anti-inflammatory diet: Reducing processed foods, added sugars, and refined carbohydrates while increasing omega-3s, fiber, and antioxidants addresses the inflammatory component of PCOS
  • DASH diet: Shown to reduce testosterone and LH levels in a 2017 RCT of PCOS women; also improves blood pressure and metabolic markers

Exercise Evidence for PCOS

  • Insulin sensitivity: Aerobic exercise improves insulin sensitivity independently of weight loss — GLUT4 translocation in muscle reduces insulin demand and ovarian androgen production
  • Menstrual regularity: Structured exercise programs (150 min/week moderate aerobic) significantly improve menstrual regularity in multiple trials
  • Androgens: Regular aerobic exercise reduces free testosterone and DHEAS in PCOS women — effect is additive with dietary intervention
  • High-Intensity Interval Training (HIIT): Produces faster improvements in insulin sensitivity than continuous moderate aerobic exercise in PCOS; practical for women with time constraints
  • Resistance training: Increases lean mass, improves insulin sensitivity, and may reduce androgen levels; particularly valuable for body composition improvement in PCOS
  • Combined exercise + diet: Consistently produces greater improvements in all PCOS outcomes than either intervention alone

Supplement Evidence for PCOS

  • Inositol (myo-inositol + D-chiro-inositol): Strongest supplement evidence for PCOS; acts as an insulin sensitizer; multiple RCTs show improved insulin sensitivity, reduced testosterone, improved menstrual regularity, and better ovulation rates; 2–4g myo-inositol/day with 40:1 myo:D-chiro ratio is the most studied protocol
  • Omega-3 fatty acids: Multiple trials show reduced testosterone and LH, improved insulin sensitivity, and lower inflammatory markers at 3g EPA+DHA/day; anti-inflammatory mechanism particularly relevant to PCOS
  • Vitamin D: Deficiency is prevalent in PCOS (67–85%); supplementation improves insulin resistance, menstrual regularity, and AMH levels in deficient women
  • Magnesium: Deficiency is associated with insulin resistance; supplementation shows modest improvements in PCOS metabolic parameters
  • N-acetylcysteine (NAC): Antioxidant with insulin-sensitizing properties; comparable to metformin in some small RCTs for insulin sensitivity and ovulation induction
  • Berberine: Multiple RCTs show comparable effects to metformin for insulin sensitivity and menstrual regularity in PCOS; 500mg 2–3x/day

Pharmacological Treatment

  • Combined oral contraceptives (COC): First-line for managing menstrual irregularity and hyperandrogenism symptoms (acne, hirsutism); reduce LH, increase SHBG (binding testosterone), and restore cycle regularity; do not treat underlying insulin resistance
  • Metformin: Insulin sensitizer; reduces insulin, testosterone, and LH; improves menstrual regularity and ovulation; first-line for metabolic PCOS (insulin resistance, prediabetes); less effective for hirsutism/acne than COC
  • Clomiphene / letrozole: Ovulation induction for fertility; letrozole now preferred over clomiphene (higher live birth rates in PCOS per NEJM 2014 trial)
  • Spironolactone: Anti-androgen used for hirsutism and acne; reduces testosterone effect at receptor level; requires contraception (teratogenic)
  • GLP-1 agonists (semaglutide): Emerging evidence for PCOS; reduce weight, insulin resistance, and androgen levels; particularly promising for overweight PCOS with metabolic features

Frequently Asked Questions

The most common symptoms are irregular or absent periods, excess facial or body hair (hirsutism), acne, scalp hair thinning, difficulty losing weight, and fertility challenges. Not all women have all symptoms — PCOS presents on a spectrum. Some women have predominantly metabolic features (insulin resistance, weight gain) while others have primarily androgenic symptoms (acne, hirsutism) with normal BMI.

PCOS cannot be cured but is highly manageable. Lifestyle interventions (diet and exercise) can normalize hormonal profiles, restore menstrual regularity, and significantly reduce long-term metabolic risks. Many women find symptoms are well controlled through a combination of diet, exercise, and targeted supplements or medication. Symptoms often improve after menopause as androgens decline.

Strongly yes. A low-GI or low-carbohydrate diet reduces insulin spikes and directly lowers ovarian androgen production. Even 5–10% weight loss significantly improves testosterone levels, menstrual regularity, and fertility in overweight PCOS women. An anti-inflammatory dietary pattern and adequate protein intake support insulin sensitivity and hormonal balance.

Inositol (particularly myo-inositol at 2–4g/day) has the strongest evidence — multiple RCTs show improvements in insulin sensitivity, testosterone, and menstrual regularity. Omega-3 fatty acids, vitamin D, and magnesium also have meaningful evidence. Berberine shows efficacy comparable to metformin in some trials. Always discuss supplements with a healthcare provider, especially when trying to conceive.

Yes — most women with PCOS can conceive, though it may take longer due to irregular ovulation. Lifestyle interventions that restore ovulation (weight loss, diet, exercise) are first-line. Letrozole is the most effective ovulation induction medication for PCOS. IVF is an option when other approaches fail. With appropriate management, PCOS-related infertility has good outcomes.

Research Summary

PCOS is the most common hormonal disorder in women of reproductive age. Insulin resistance is the central therapeutic target — lifestyle interventions produce significant improvements in all PCOS outcomes.

  • Evidence strength: Moderate-Strong (4/5)
  • Prevalence: 8–13% of women of reproductive age
  • Core mechanism: Insulin resistance drives androgen excess in 50–70% of cases
  • Most effective lifestyle intervention: 5–10% weight loss in overweight women
  • Best supplement: Myo-inositol (2–4g/day) — multiple RCTs for insulin and androgens
  • First-line medications: COC (symptoms) or metformin (metabolic) or letrozole (fertility)
⚠️ Medical Disclaimer: This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any health decisions.

References

All studies cited are peer-reviewed. DOI and PubMed links open in a new tab.

  1. 1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reproduction, 19(1), 41–47. doi:10.1093/humrep/deh098 PMID:14688154
  2. 2. Azziz R, Carmina E, Chen Z, et al. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2, 16057. doi:10.1038/nrdp.2016.57 PMID:27510637
  3. 3. Unfer V, Carlomagno G, Dante G, Facchinetti F (2012). Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological Endocrinology, 28(7), 509–515. doi:10.3109/09513590.2011.650660 PMID:22296306
  4. 4. Legro RS, Brzyski RG, Diamond MP, et al. (2014). Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. New England Journal of Medicine, 371(2), 119–129. doi:10.1056/NEJMoa1313517 PMID:25006718
  5. 5. Harrison CL, Lombard CB, Moran LJ, Teede HJ (2011). Exercise therapy in polycystic ovary syndrome: a systematic review. Human Reproduction Update, 17(2), 171–183. doi:10.1093/humupd/dmq045 PMID:20833639
  6. 6. Mavropoulos JC, Yancy WS, Hepburn J, Westman EC (2005). The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. Nutrition & Metabolism, 2, 35. doi:10.1186/1743-7075-2-35 PMID:16359551
  7. 7. Teede HJ, Misso ML, Costello MF, et al. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 33(9), 1602–1618. doi:10.1093/humrep/dey256 PMID:30052961
  8. 8. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R (1998). Effects of Metformin on Spontaneous and Clomiphene-Induced Ovulation in the Polycystic Ovary Syndrome. New England Journal of Medicine, 338(26), 1876–1880. doi:10.1056/NEJM199806253382602 PMID:9637806